Your browser version is outdated. We recommend that you update your browser to the latest version.

Board of Directors

 

Chairman of the Board: Peter Birk, PhD

Dr. Birk is an experienced business accelerator and investor and part of the Accelerace Management team. Dr Birk has a background from management positions in the biotech industry as VP in EpiTherapeutics and Pharmexa, and CSO in ACE BioSciences. Dr Birk has a strong experience in the field of vaccines and immunotherapy, enabling him to strengthen MonTa Biosciences in both business and R&D. See more about Dr Birk here.

 

 

BoD member: Esper Boel, PhD, CSO at Paratech A/S

Dr. Boel is former CVP and head of Biotechnology at Novo Nordisk A/S and former CSO of Discovery at Symphogen A/S. He was centrally involved in building the inflammation and oncology portfolio at Novo Nordisk A/S from 2002 to 2013. Dr. Boel has held key strategic, consulting and advisory positions in several biotech companies with a focus on immunotherapy, making Dr. Boel a well-respected expert in R&D, business development and strategic aspects. See more about Dr Boel here.

  

 

BoD Member: Thomas Lars Andresen, PhD., Professor

Prof. Andresen is Department Head of DTU Nanotech and group leader of the CBIO group at DTU Nanotech and is head of the DTU Center for Nanomedicine and Theranostics. Prof Andresen is experienced in biotech start-ups and founded NANOVI in 2011 and Torque in 2015. Prof. Andresen is expert in biomaterial engineering for drug delivery and imaging applications, and very experienced in the fields of organic chemistry, biophysics, nanotechnology and nanomedicine, drug delivery and cancer biology. See more about Prof. Andresen here.

 

 

BoD MJørgen Drejer, CEO SanionaJørgen Drejer, CEO Sanionaember: Jørgen Drejer, PhD, CEO and founder of Saniona

Dr. Drejer is a serial entrepreneur and have co-founded several biotech companies in Denmark, US, Canada and Sweden, including Saniona AB listed on Nasdaq Stockholm. Dr. Drejer has been key for entering research collaborations and partnerships with large pharma companies, for raising capital and negotiating license and partnership agreements . Dr. Drejer bring strong competencies to MonTa Biosciences in entrepreneurship, investor relations, IPOs and management of research and development activities, and a very large network in the biotech and pharmaceutical industry. See more about Dr. Drejer here.